Immunomodulatory fusion proteins
US12054530B2 · kind B2 · utility
0Cited by
10References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 15, 2021 |
| Grant date | Aug 6, 2024 |
| Priority date | — |
| Expiry date | Jul 22, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/10371
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., a TGFβ trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion proteins, or expression vectors encoding for the fusion proteins, e.g., oncolytic adenoviral expression vectors, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.